<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05011409</url>
  </required_header>
  <id_info>
    <org_study_id>06-2020</org_study_id>
    <nct_id>NCT05011409</nct_id>
  </id_info>
  <brief_title>Prevalence of Depression and Anxiety Among Breast Cancer Patients</brief_title>
  <official_title>Prevalence of Depression and Anxiety Symptoms Among Newly Diagnosed Breast Cancer Patients in Almaty, Kazakhstan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kazakh Medical University of Continuing Education</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Malaya</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kazakh Medical University of Continuing Education</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Depression and anxiety in patients with breast cancer is serious comorbidity that affects the&#xD;
      quality of life for patients, and their survival rates as they have poorer health outcomes.&#xD;
      Furthermore, patients' high psychological burden is linked to higher healthcare costs. The&#xD;
      investigation of the depression and anxiety symptoms prevalence among newly diagnosed breast&#xD;
      cancer patients will help to navigate the health policy adjustment and psycho-social support&#xD;
      system requirements. This study aims to investigate the prevalence of depression and anxiety&#xD;
      symptoms among newly diagnosed breast cancer patients in Almaty, Kazakhstan, and associated&#xD;
      risk factors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of Depression Symptoms</measure>
    <time_frame>within 6 months of diagnosis</time_frame>
    <description>Prevalence of depression symptoms among newly diagnosed breast cancer patients according to the Beck Depression Inventory-II (BDI-II). The 21-item self-administered survey is scored on a scale of 0-3 in a list of four statements arranged in increasing severity about a particular symptom of depression. Each of the 21 items corresponding to a symptom of depression is summed to give a single score for the Beck Depression Inventory-II (BDI-II). There is a four-point scale for each item ranging from 0 to 3. p. On two items (16 and 18) there are seven options to indicate either an increase or decrease of appetite and sleep. Cut-off score guidelines for the BDI-II are given with the recommendation that thresholds be adjusted based on the characteristics of the sample, and the purpose for use of the BDI-II. Total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of Anxiety Symptoms</measure>
    <time_frame>within 6 months of diagnosis</time_frame>
    <description>Prevalence of anxiety symptoms among newly diagnosed breast cancer patients according to the Beck Anxiety Inventory. The Beck Anxiety Inventory (BAI) consists of 21 self-reported items (four-point scale ranging from 0 to 3. p.) used to assess the intensity of physical and cognitive anxiety symptoms during the past week. Scores may range from 0 to 63: minimal anxiety levels (0-7), mild anxiety (8-15), moderate anxiety (16-25), and severe anxiety (26-63).</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">142</enrollment>
  <condition>Depression</condition>
  <condition>Anxiety</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Newly diagnosed breast cancer patients</arm_group_label>
    <description>Newly diagnosed breast cancer patients referred to Kazakh Institute of Oncology and Radiology or Almaty Oncology Center will be assessed on the prevalence of depression and anxiety symptoms.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Study population will include breast cancer patients with confirmed diagnosis referred to&#xD;
        the treatment to the Kazakh Institute of Oncology and Radiology and the Almaty Oncology&#xD;
        Center&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female adults with confirmed diagnosis of breast cancer within the 6 months study&#xD;
             enrollment&#xD;
&#xD;
          -  TNM stage I-IV&#xD;
&#xD;
          -  Russian or Kazakh language proficiency&#xD;
&#xD;
          -  Ability to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current psychotic disorder, manic episode, serious neurological disorder, intellectual&#xD;
             disability, or developmental disorder&#xD;
&#xD;
          -  Current active suicidal ideation&#xD;
&#xD;
          -  Referral to palliative care&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female breast cancer patients, not based on the self-representation of gender identity</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Indira A Karibayeva, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kazakh Medical University of Continuing Education</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Indira A Karibayeva, MPH</last_name>
    <phone>+77712180879</phone>
    <email>indira.karibayeva@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Botagoz S Turdaliyeva, Professor</last_name>
    <phone>+77471264725</phone>
    <email>b.turdaliyeva@kazmuno.kz</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Almaty Oncology Center</name>
      <address>
        <city>Almaty</city>
        <zip>050000</zip>
        <country>Kazakhstan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Berik A Kaibullayev, MD</last_name>
      <phone>+77273122488</phone>
      <phone_ext>026</phone_ext>
    </contact>
    <investigator>
      <last_name>Indira A Karibayeva, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kazakh Institute of Oncology and Radiology</name>
      <address>
        <city>Almaty</city>
        <zip>050000</zip>
        <country>Kazakhstan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ilmira R Khussainova</last_name>
      <phone>.+7(727)2921064</phone>
      <email>edu@onco.kz</email>
    </contact>
    <investigator>
      <last_name>Indira A Karibayeva, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Kazakhstan</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 19, 2021</study_first_submitted>
  <study_first_submitted_qc>August 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2021</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>depression</keyword>
  <keyword>anxiety</keyword>
  <keyword>breast cancer</keyword>
  <keyword>prevalence</keyword>
  <keyword>Beck Depression Inventory</keyword>
  <keyword>Beck Anxiety Inventory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>This plan is to be determined</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

